# Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

> **NCT02919306** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 27 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **BIOLOGICAL:** Ad26.Mos.HIV
- **BIOLOGICAL:** MVA-Mosaic
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02919306
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919306, "Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02919306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*